Waters Corp（WAT）财务数据WATWaters Corp

Waters Corp (WAT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Chemistry Consumables, accounting for 42.9% of total sales, equivalent to $543.00M. Other significant revenue streams include Waters Instrument Systems and TA Instrument Systems. Understanding this composition is critical for investors evaluating how WAT navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Waters Corp maintains a gross margin of 29.79%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 0.67%, while the net margin is -8.27%. These profitability ratios, combined with a Return on Equity (ROE) of 1.91%, provide a clear picture of how effectively WAT converts its operational activities into shareholder value.

In the context of the broader market, WAT competes directly with industry leaders such as IDXX and ILMN. With a market capitalization of $43.64B, it holds a leading position in the sector. When comparing efficiency, WAT's gross margin of 29.79% stands against IDXX's 63.71% and ILMN's 66.44%. Such benchmarking helps identify whether Waters Corp is trading at a premium or discount relative to its financial performance.

Waters Corp has shown strong revenue growth, with Q2 2026 revenue reported at $1.645 billion, up from $799.89 million in Q3 2025. However, net income has turned negative in the last two quarters, with Q2 2026 showing a loss of $136 million, which is a significant concern.